Privately-owned Lykos Therapeutics continues to reel from its devastating rejection by the Food & Drug Administration (FDA) for the company’s MDMA drug. The company announced that...
Psychedelics are being considered for various mental health issues like drug-resistant depression and post traumatic stress disorder. Now they are being studied for treating addictive behaviors...
Awakn will also partner with Charnwood Discovery to help it synthesize the new compounds for further testing. Canadian biotech firm Awakn Life Sciences Corp. (CSE: AWKN)...
Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) released its financial results for the first quarter ending June 30, 2024. Red Light‘s revenue grew from last...
An administrative law judge with the Drug Enforcement Administration has scheduled a 10-day hearing for rulemaking related to the potential ban of two psychedelic compounds. The...
Anyone wishing to speak at the meeting must register in advance by Tuesday, Sept. 3 on the FDA website. The U.S. Food and Drug Administration has...
Psilera’s psilocybin drug is non-hallucinogenic. Psilera Inc. reported positive results in initial studies of its non-hallucinogenic psilocybin drug that it plans to use in dementia treatments....